Phlexglobal, the UK-based contract research organisation (CRO) that specialises in clinical trial administration services such as document management and ethics committee submissions, has announced a new board of directors to “help continue the company’s unprecedented growth”.

The new board is led by Nicola Murgatroyd, founder of Phlexglobal and now the CRO’s chief executive officer (CEO). Former CEO Nigel Murgatroyd joins the board in his new capacity as commercial director.

Also stepping up to the new board are Karen Roy, Phlexglobal’s former head of business development, who successfully launched the company’s PhlexEview Trial Master File (TMF) solution last year and has taken up the position of global business development director; and Stella Donoghue, recently appointed as Phlexglobal’s finance director.

“Stella specialises in supporting entrepreneurial SMEs [small and medium-sized enterprises] in their high-growth phase which, together with Nigel’s extensive commercial experience, will facilitate Phlexglobal’s ventures into new markets and territories,” the company commented.

Earlier this year Phlexglobal said it hoped to open a US facility during the summer to capitalise on increasing interest in PhlexEview. The CRO is also looking to expand into Europe with its TMF solutions and associated services such as Task Force and Training.

Ray Clarke, founder and managing director of Datacare Business Systems Ltd, and Stephen Swiatek, UK sales director with an unspecified pan-European German company, are joining the Phlexglobal board as non-executive directors.

Over the past 24 months the CRO has doubled in size, with a forecast turnover of £5 million for 2008, rising to £10 million by 2010.